scholarly article | Q13442814 |
P356 | DOI | 10.1097/01.WNF.0000240943.59617.4C |
P698 | PubMed publication ID | 17414939 |
P50 | author | Parkinson Study Group | Q98686625 |
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Parkinson's disease | Q11085 |
levodopa | Q300989 | ||
P304 | page(s) | 72-85 | |
P577 | publication date | 2007-03-01 | |
P1433 | published in | Clinical Neuropharmacology | Q15753218 |
P1476 | title | Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage | |
P478 | volume | 30 |
Q30240991 | A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. |
Q37736512 | Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis |
Q35837892 | Dyskinesias and treatment with pramipexole in patients with Parkinson's disease |
Q24234273 | Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications |
Q38476557 | Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease |
Q28283547 | Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease |
Q39094808 | Integrating Patient Concerns into Parkinson's Disease Management |
Q37236732 | Minority enrollment in Parkinson's disease clinical trials |
Q92593925 | Parkinson's disease in the Western Pacific Region |
Q38762150 | Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus |
Q92583206 | Prevalence and Correlates of Anti-Parkinson Drug Use in a Nationally Representative Sample |
Q37974751 | Progression of motor symptoms in Parkinson's disease |
Q37685687 | Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life |
Q37643888 | The Treatment of Sleep Disorders in Parkinson's Disease: From Research to Clinical Practice. |
Q28270780 | Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials |
Q33796430 | Treatment disparities in Parkinson's disease |
Q36842189 | Update on the use of pramipexole in the treatment of Parkinson's disease |
Q33519672 | Why do some promising brain-stimulation devices fail the next steps of clinical development? |
Search more.